NCT01434459: Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin |
|
|
| Terminated | 1 | 9 | US | Gemcitabine with TheraSphere, TheraSphere_radioembolization, Gemcitabine- Gemzar | Emory University | Pancreatic Neoplasms, Cholangiocarcinoma | 01/14 | 09/14 | | |
NCT00846131: Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma |
|
|
| Completed | 1 | 24 | US | Sorafenib, BAY 54-9085 is the tosylate salt of BAY 43-9006; NEXAVAR®, Yttrium-90 (Y-90), Radioembolization, Therasphere | Northwestern University, National Cancer Institute (NCI) | Hepatocellular Carcinoma | 07/15 | 09/16 | | |
NCT01730157: Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases |
|
|
| Terminated | 1 | 6 | US | ipilimumab, anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody, MDX-010, MDX-CTLA-4, monoclonal antibody CTLA-4, yttrium Y 90 glass microspheres, TheraSphere, laboratory biomarker analysis | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma | 02/16 | 02/16 | | |
NCT01864070: Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease |
|
|
| Withdrawn | 1 | 0 | US | TheraSphere, Everolimus, Afinitor, Zortress, RAD001, Phone Call | M.D. Anderson Cancer Center, BTG International Inc., Novartis Pharmaceuticals | Liver Cancer | 05/18 | | | |
